Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL8326 in Small Cell Lung Cancer
NCT04890795Phase 2Unknown
- Sponsor
- Advenchen Laboratories
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AL8326 in small cell lung cancer (SCLC), sponsored by Advenchen Laboratories. Status: unknown.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04890795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890795.